To test the association between CD38 expression and isatuximab-mediated ADCC, selected MM cell lines (JJN-3, NCI-H929, and RPMI-8226) were treated for 48 h with ATRA, a potent CD38 inducer (34, 35), thus increasing CD38 expression (>100,000 molecules/cell) (Figure 3B). The gene discussed is CD38; the disease is Miyoshi myopathy.